Thomas Trolle

Company: Evaxion Biotech

Job title: Director, Bioinformatics & AI/ML

Seminars:

Beyond Neoantigens: Alternative Sources of Antigens for Personalized Cancer Immunotherapy 12:00 pm

Neoantigen vaccines are primarily being tested in patients with high mutational burden cancers such as melanoma and NSCLC Patients with lower mutational burden cancers are less likely to have good, targetable neoantigens Looking beyond neoantigens has the potential to make personalized cancer vaccines relevant for more patientsRead more

day: Pre-Conference Focus Day